Derisking Orphan Drug Programs in 2020 and Beyond
Summary: Developing therapies for rare diseases has always come with a unique set of challenges. Now, a pandemic has dramatically shifted the attention of the industry and introduced new hurdles – forcing orphan developers into a critical re-examination of their go-to-market strategies. In this webinar, Endpoints convenes four orphan drug developers who will share what they’ve learned so far and detail how they plan to fortify their programs. We’ll also release results of our Orphan Drug Survey, which will provide additional insights from hundreds of Endpoints readers at orphan drug companies.